TORONTO / Feb 29, 2024 / Business Wire / Biomind Labs Inc. (“ Biomind ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, today announced the successful conclusion of the Phase 2 clinical trial of its proprietary... Read More